Journey Medical (DERM) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Journey Medical (DERM) over the past year, gaining 0.9% versus a loss of 55.8%. Over five years, DERM leads with a -61.1% price change compared with -96.8% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($95.3 million vs $93.2 million), about 1.0 times the size.
Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -2336.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | NRXP |
|---|---|---|
| Share price | $3.30 | $2.15 |
| Market cap | $93.16M | $95.31M |
| 1-day change | -7.04% | -15.69% |
| YTD return | -57.20% | -20.66% |
| 1-year return | -55.76% | +0.94% |
| 5-year return | -61.13% | -96.81% |
| EPS (TTM) | $-0.18 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $61.86M | $1.23M |
| Revenue growth (YoY) | +10.20% | — |
| Net income (latest FY) | $-11.43M | $-28.62M |
| Gross margin | 66.17% | 58.78% |
| Operating margin | -13.21% | -1324.41% |
| Net margin | -18.48% | -2336.49% |
| 52-week high | $9.56 | $5.06 |
| 52-week low | $3.21 | $1.62 |
| Distance from 52-week high | -65.46% | -57.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +286.36% | +1702.33% |
| Average volume | 190.39K | 1.07M |
| Shares outstanding | 22.23M | 44.33M |
| Employees | 58 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed DERM by 56.7 percentage points over the past year.
- Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -2336.5 cents for NRX Pharmaceuticals.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
DERM vs NRXP FAQ
Which is bigger, Journey Medical or NRX Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $95.31M compared with $93.16M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or NRXP?
NRXP returned +0.94% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.